Literature DB >> 18436808

Mouse CD36 has opposite effects on LDL and oxidized LDL metabolism in vivo.

Vilayphone Luangrath1, Mathieu R Brodeur, David Rhainds, Louise Brissette.   

Abstract

OBJECTIVE: The cluster of differentiation-36 (CD36) is a multifunctional protein which is recognized for its in vitro ability to take up oxidized low-density lipoproteins (oxLDL) in macrophages and is therefore considered atherogenic. It also binds LDL. Our objective was to define the physiological role of CD36 in both native LDL and oxLDL metabolism in mice. METHODS AND
RESULTS: Clearance studies of labeled LDL and oxLDL were conducted in wild-type, CD36 knockout (KO), scavenger receptor class B, type I (SR-BI) KO, and SR-BI/CD36 double KO mice. We found that CD36 impedes the disappearance of native LDL and favors that of oxLDL. This was confirmed by association and degradation assays with primary cultures of hepatic cells from wild-type and CD36 KO mice. In addition, our in vivo work indicates that neither SR-BI nor CD36 plays a significant role in cholesteryl esters (CE) selective uptake (SU) from oxLDL, whereas CD36, in absence of SR-BI, can selectively take CE from LDL.
CONCLUSIONS: Our investigation showed for the first time that CD36 plays a significant role in oxLDL uptake in vivo in the mouse. As CD36 also retards LDL clearance, its atherogenic character may also relate to its negative effect on LDL catabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18436808     DOI: 10.1161/ATVBAHA.107.161653

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  13 in total

1.  Scavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells.

Authors:  May Brundert; Joerg Heeren; Martin Merkel; Antonella Carambia; Johannes Herkel; Peter Groitl; Thomas Dobner; Rajasekhar Ramakrishnan; Kathryn J Moore; Franz Rinninger
Journal:  J Lipid Res       Date:  2011-01-09       Impact factor: 5.922

Review 2.  CD36 genetics and the metabolic complications of obesity.

Authors:  Latisha Love-Gregory; Nada A Abumrad
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2011-11       Impact factor: 4.294

3.  Dyslipidemia: a prospective controlled randomized trial of intensive glycemic control in sepsis.

Authors:  Sylas B Cappi; Danilo T Noritomi; Irineu T Velasco; Rui Curi; Tatiana C A Loureiro; Francisco G Soriano
Journal:  Intensive Care Med       Date:  2012-02-02       Impact factor: 17.440

4.  CD36 goes native.

Authors:  Maria Febbraio
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07       Impact factor: 8.311

5.  Enhanced hepatic apoA-I secretion and peripheral efflux of cholesterol and phospholipid in CD36 null mice.

Authors:  Pin Yue; Zhouji Chen; Fatiha Nassir; Carlos Bernal-Mizrachi; Brian Finck; Salman Azhar; Nada A Abumrad
Journal:  PLoS One       Date:  2010-03-26       Impact factor: 3.240

6.  Sarcolipin and ubiquitin carboxy-terminal hydrolase 1 mRNAs are over-expressed in skeletal muscles of alpha-tocopherol deficient mice.

Authors:  Vihas T Vasu; Sean Ott; Brad Hobson; Vania Rashidi; Saji Oommen; Carroll E Cross; Kishorchandra Gohil
Journal:  Free Radic Res       Date:  2009-02

7.  Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation.

Authors:  Klementina Fon Tacer; Damjana Rozman
Journal:  J Lipids       Date:  2011-07-02

8.  Low-bone-mass phenotype of deficient mice for the cluster of differentiation 36 (CD36).

Authors:  Olha Kevorkova; Corine Martineau; Louise Martin-Falstrault; Jaime Sanchez-Dardon; Louise Brissette; Robert Moreau
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

9.  Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.

Authors:  Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Akinobu Nakamura; Hideaki Miyoshi; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Koji Yamamoto; Taku Shigesawa; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Journal:  J Gastroenterol       Date:  2020-11-19       Impact factor: 7.527

10.  Scavenger receptor class B, type I (Scarb1) deficiency promotes osteoblastogenesis but stunts terminal osteocyte differentiation.

Authors:  Corine Martineau; Olha Kevorkova; Louise Brissette; Robert Moreau
Journal:  Physiol Rep       Date:  2014-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.